### Neuroendocrine

<table>
<thead>
<tr>
<th>Pancreas</th>
<th>Intestines</th>
<th>Lung &amp; Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Grade (G1/G2)</td>
<td>Low Grade (G1/G2)</td>
<td>Low Grade (G1/G2)</td>
</tr>
<tr>
<td>High Grade (G3)</td>
<td>High Grade (G3)</td>
<td>High Grade (G3)</td>
</tr>
</tbody>
</table>

- **Symptom control/Non-Interventional/Translational**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **Adjuvant**
  - SECTOR
  - NCRS528
  - AFINITOR

- **Neoadjuvant Surgery**
  - TELESTAR: Safety & efficacy of Telotristat Etiprate in patients with carcinoid syndrome - A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog SSA Therapy
  - OBLIQUE - A Phase IV Observational study to assess the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymus
  - CALM-NET: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of lanreotide Autogel® to treat the Symptoms of Functioning Midgut Neuroendocrine Tumours (NET)
  - TELEPATH: A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
  - TELECAST: Telotristat Etiprate for Carcinoid Syndrome Therapy

- **Advanced 1st Line**
  - SECTOR
  - NCRS528
  - AFINITOR

- **Advanced 2nd Line**
  - CANC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **High Grade**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **Low Grade**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **Academically-sponsored**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **Industry-sponsored**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **Academic/Industry Partnership**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **CSG-sponsored**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **CSG Consulted**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **Industry-sponsored**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **UP RECRUITING**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **UP FUNDED**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **UP IN SET**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **UP OPEN**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

- **UP OPEN/RECRUITING**
  - CASC - 3621
  - NCRS502
  - OBLIQUE
  - VIBRANT

Version: February 2015